VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

References

• Sonneveld P, Michiels J J. Full-dose chemotherapy in elderly patients with non-Hodgkin lymphoma. A feasibility study using a mitoxantrone-containing regimen. Br J Cancer 1990; 62: 105–108
   PubMed Web of Science ®Google Scholar
• Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, Carbone A, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• O'Reilly S E, Klimo P, Connors J M. Low dose ACOP-B and VABE. Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, et al. P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 2362–2369
   PubMed Web of Science ®Google Scholar
• Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, et al. P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994; 5: 895–900
   PubMed Web of Science ®Google Scholar
• Armitage J O, Dick F R, Corder M P, Garneau S C, Platz C E, Slymen D J. Predicting therapeutic outcome in patients with diffuse histiocitic lymphoma treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Cancer 1982; 50: 1695–1702
   PubMed Web of Science ®Google Scholar
• Vose J M, Armitage J O, Weisemburger D D, Bierman P J, Sorensen S, Hutcins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Bendandi M, Gherlinzoni F, Mazza P, Salvucci M, Aitini E, et al. VNCOP-B regimen in the treatment of high grade non-Hodgkin's lymphoma in the elderly. Hematologica 1993; 78: 378–382
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pavone E, Storti S, Moretti L, Fattori P P, Guardigni L, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974–3979
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, De Renzo A, et al. Randomized trial of 8-week versus 12-week NCOP-B plus G-CSF regimes as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13: 1364–1369
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Buoabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse late B-cell lymphoma. N Eng J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Freugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Pfeundschuh M G, Kloess M, Zeylanova S, Lengfelder E, Franke A, Reiser M, et al. Six vs eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large-B cell lymphoma (DLBCL). Results of the completed RICOVER-60 trial of the German High Grade non-Hodgkin lymphoma Study Group (DSHNHL). Blood (Suppl.) 2006; 108: 205A
   Google Scholar
• Harris N L, Jaffe E S, Dielbod J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K. Report of the committee on Hodgkin's disease staging classifications. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning J S, Coiffier B, Shipp M A, Fisher R I, Connor J M, et al. Report of international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Non-parametric estimation from incomplete observations. JAMA 1958; 53: 457–481
   Web of Science ®Google Scholar